Why the study?
Does intravenous bosentan improve hemodynamics in patients with severe pulmonary hypertension?
Population
Patients with severe pulmonary hypertension, including those resistant to inhaled nitric oxide
Design
Other
Authors
Loading...
Systemic hypotension limits intravenous bosentan utility in pulmonary hypertension; leaves open oral endothelin antagonism for clinical evaluation.
Does intravenous bosentan improve hemodynamics in patients with severe pulmonary hypertension?
Intravenous bosentan is a potent pulmonary vasodilator in severe pulmonary hypertension, but its clinical utility via this route is limited by systemic hypotension.
Williamson et al. (2000) studied this question.